148 related articles for article (PubMed ID: 38414188)
21. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic Stem-Cell Transplantation: Exploring the Latest Advances and Gaps in Disparities, Psychosocial and Symptom Management Interventions, and Chronic Graft-Versus-Host Disease Care.
Trunk AD; Guo M; Budvytyte L; Islam NS; Khera N; Hamilton BK; Amonoo HL
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432186. PubMed ID: 38754066
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
[TBL] [Abstract][Full Text] [Related]
25. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.
Atsuta Y; Hirakawa A; Nakasone H; Kurosawa S; Oshima K; Sakai R; Ohashi K; Takahashi S; Mori T; Ozawa Y; Fukuda T; Kanamori H; Morishima Y; Kato K; Yabe H; Sakamaki H; Taniguchi S; Yamashita T;
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1702-1709. PubMed ID: 27246369
[TBL] [Abstract][Full Text] [Related]
26. Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment.
Muffly L
Curr Hematol Malig Rep; 2015 Mar; 10(1):28-34. PubMed ID: 25500987
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.
Yuan J; Pei R; Su W; Cao J; Lu Y
Oncotarget; 2017 Feb; 8(7):10871-10882. PubMed ID: 28107198
[TBL] [Abstract][Full Text] [Related]
28. Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.
Singh N; Loren AW
Clin Chest Med; 2017 Dec; 38(4):575-593. PubMed ID: 29128011
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
[TBL] [Abstract][Full Text] [Related]
30. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
[TBL] [Abstract][Full Text] [Related]
31. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.
Friend BD; Broglie L; Logan BR; Chhabra S; Bupp C; Schiller G; Beitinjaneh A; Perez MAD; Guilcher GMT; Hashem H; Hildebrandt GC; Krem MM; Lazarus HM; Nishihori T; Nusrat R; Rotz SJ; Wirk B; Wieduwilt M; Pasquini M; Savani BN; Stadtmauer EA; Sorror ML; Thakar MS
Transplant Cell Ther; 2023 Feb; 29(2):123.e1-123.e10. PubMed ID: 36442769
[TBL] [Abstract][Full Text] [Related]
32. Quality of life after allogeneic hematopoietic cell transplantation.
Pidala J; Anasetti C; Jim H
Blood; 2009 Jul; 114(1):7-19. PubMed ID: 19336756
[TBL] [Abstract][Full Text] [Related]
33. Nonmyeloablative allogeneic hematopoietic cell transplantation.
Storb R; Sandmaier BM
Haematologica; 2016 May; 101(5):521-30. PubMed ID: 27132278
[TBL] [Abstract][Full Text] [Related]
34. Emerging drugs for acute graft-versus-host disease.
Khaled Y; Reddy P; Krijanovski O
Expert Opin Emerg Drugs; 2009 Jun; 14(2):219-32. PubMed ID: 19519285
[TBL] [Abstract][Full Text] [Related]
35. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.
Saad A; Loren A; Bolaños-Meade J; Chen G; Couriel D; Di Stasi A; El-Jawahri A; Elmariah H; Farag S; Gundabolu K; Gutman J; Ho V; Hoeg R; Horwitz M; Hsu J; Kassim A; Kharfan Dabaja M; Magenau J; Martin T; Mielcarek M; Moreira J; Nakamura R; Nieto Y; Ninos C; Oliai C; Patel S; Randolph B; Schroeder M; Tzachanis D; Varshavsky-Yanovsky AN; Vusirikala M; Algieri F; Pluchino LA
J Natl Compr Canc Netw; 2023 Feb; 21(2):108-115. PubMed ID: 36791762
[TBL] [Abstract][Full Text] [Related]
36. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
[TBL] [Abstract][Full Text] [Related]
37. Beyond steroids: A systematic review and proposed solutions to managing acute graft-versus-host disease in adolescents and young adults.
Friend BD; Schiller GJ
Blood Rev; 2022 Mar; 52():100886. PubMed ID: 34509319
[TBL] [Abstract][Full Text] [Related]
38. To D or not to D: vitamin D in hematopoietic cell transplantation.
Hong S; Ferraro CS; Hamilton BK; Majhail NS
Bone Marrow Transplant; 2020 Nov; 55(11):2060-2070. PubMed ID: 32335583
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
Sorror ML; Sandmaier BM; Storer BE; Franke GN; Laport GG; Chauncey TR; Agura E; Maziarz RT; Langston A; Hari P; Pulsipher MA; Bethge W; Sahebi F; Bruno B; Maris MB; Yeager A; Petersen FB; Vindeløv L; McSweeney PA; Hübel K; Mielcarek M; Georges GE; Niederwieser D; Blume KG; Maloney DG; Storb R
JAMA; 2011 Nov; 306(17):1874-83. PubMed ID: 22045765
[TBL] [Abstract][Full Text] [Related]
40. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
